Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5889291 | 0.83 | IKBKB (0.42) | ARADORA3HSD11B1AKR1C3ALDH1A1 | |
| SCHEMBL16344586 | 0.79 | MEN1 (0.42) | ARADORA3HSD11B1AKR1C3ALDH1A1 | |
| SCHEMBL621942 | 0.73 | BRD4 (0.47) | CREBBPBRD4 | |
| SCHEMBL5083830 | 0.73 | IDO1 (0.58) | ALDH1A1MEN1KMT2AMAPTHPGD | |
| SCHEMBL28094389 | 0.73 | MTNR1A (0.36) | ARADORA3HSD11B1AKR1C3MEN1 | |
| SCHEMBL5323806 | 0.72 | ALDH1A1 (0.35) | ALDH1A1CREBBPBRD4EP300SMN1; SMN2 | |
| SCHEMBL9818019 | 0.72 | IDO1 (0.61) | ALDH1A1CYP2C19 | |
| Phosphonic Acid SCHEMBL4427162 | 0.71 | BRD4 (0.42) | ALDH1A1TSHRMAPTCREBBPBRD4 | |
| SCHEMBL157619 | 0.70 | BRD4 (0.50) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL6247618 | 0.70 | BRD4 (0.50) | ALDH1A1MEN1KMT2AGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008124505-A2 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS,INC. (US) | 2008-10-16 | — | — | WO | claimed |
| US-20200113968-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR DOWNREGULATION OF PRO-INFLAMMATORY CYTOKINES | BAUSCH HEALTH IRELAND LTD (IE) | 2020-04-16 | — | — | US | disclosed |
| US-10597424-B2 | Agonists of guanylate cyclase and their uses | BAUSCH HEALTH IRELAND LIMITED (IE) | 2020-03-24 | — | — | US | disclosed |
| CN-105963676-B | Agonists of guanylate cyclase for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstones, obesity and other cardiovascular diseases | 药物协和股份有限公司 | 2020-02-18 | — | — | CN | disclosed |
| US-20190263861-A1 | AGONISTS OF GUANYLATE CYCLASE AND THEIR USES | JPMORGAN CHASE BANK, N.A. | 2019-08-29 | — | — | US | disclosed |
| US-20190262420-A1 | COMPOSITIONS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | SYNERGY PHARMACEUTICALS INC (US) | 2019-08-29 | — | — | US | disclosed |
| US-10238712-B2 | Compositions useful for the treatment of gastrointestinal disorders | SYNERGY PHARMACEUTICALS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10118946-B2 | Agonists of guanylate cyclase and their uses | SYNERGY PHARMACEUTICALS INC. (US) | 2018-11-06 | — | — | US | disclosed |
| EP-3357502-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF COLON CANCER | Synergy Pharmaceuticals Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20170349630-A1 | AGONISTS OF GUANYLATE CYCLASE AND THEIR USES | JPMORGAN CHASE BANK, N.A. | 2017-12-07 | — | — | US | disclosed |
| US-20110160225-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2011069038-A2 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, CORONARY HEART DISEASE, GALLSTONE, OBESITY AND OTHER CARDIOVASCULAR DISEASES | SYNERGY PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20100215779-A1 | Compositions and Methods for Treating Disorders Associated with Salt or Fluid Retention | IRONWOOD PHARMACEUTICALS, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100152118-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, CORONARY HEART DISEASE, GALLSTONE, OBESITY AND OTHER CARDIOVASCULAR DISEASES | SYNERGY PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100144864-A1 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| EP-2152266-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH SALT OR FLUID RETENTION | Ironwood Pharmaceuticals, Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20090054450-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2008157537-A2 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008137318-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH SALT OR FLUID RETENTION | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008124505-A2 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS,INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10238712-B2 | Compositions useful for the treatment of gastrointestinal disorders | GUCY1A1, TNF, GUCY1A2 | AR 3460/4885ADORA3 132/4885HSD11B1 1889/4885 |
| US-20190262420-A1 | COMPOSITIONS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | GUCY1A1, TNF, GUCY1A2 | AR 3460/4885ADORA3 132/4885HSD11B1 1889/4885 |
| US-20200113968-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR DOWNREGULATION OF PRO-INFLAMMATORY CYTOKINES | GUCY1A1, GUCY1A2, GUCY1B2 | AR 3850/4885ADORA3 538/4885HSD11B1 974/4885 |
| US-20100144864-A1 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS | GUCY1A2, GUCY1B2, GUCY1B1 | AR 4439/4885ADORA3 2932/4885HSD11B1 268/4885 |
| US-20110160225-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | LIPC, PNLIP, LIPA | AR 3759/4885ADORA3 2883/4885HSD11B1 114/4885 |
| US-20090054450-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | LIPC, PNLIP, LIPA | AR 3759/4885ADORA3 2883/4885HSD11B1 114/4885 |
| US-20100215779-A1 | Compositions and Methods for Treating Disorders Associated with Salt or Fluid Retention | SLC10A2, SLC10A1, SLC26A3 | AR 4282/4885ADORA3 1239/4885HSD11B1 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.